Invion : Investor Presentation

For personal use only

ASX ANNOUNCEMENT

INVESTOR PRESENTATION TO BROKERS AND INSTITUTIONAL INVESTORS

MELBOURNE (AUSTRALIA) 03 February 2022: Invion Limited (ASX: IVX) ("Invion" or the "Company") would like to release the attached investor presentation, which Invion will be using at meetings with brokers and institutional investors over the coming weeks.

This announcement was approved for release by Thian Chew, Chairman of the Board.

____________________________________________

About Invion

Invion is a life-science company that is leading the global research and development of PhotosoftTM technology for the treatment of a range of cancers, atherosclerosis and infectious diseases. Invion holds the exclusive Australia and New Zealand license rights and exclusive distribution rights to Asia Pacific excluding China (other than Hong Kong, which is included in the Territory), Macau, Taiwan, Japan and South Koreato the PhotosoftTM technology for all cancer indications. It also holds the exclusive rights to the technology in Asia Pacific (excluding Greater China) for atherosclerosis and infectious diseases. Research and clinical cancer trials are funded by the technology licensor, RMW Cho Group Limited, via an R&D services agreement with the Company. Invion is listed on the ASX (ASX: IVX).

About Photodynamic Therapy (PDT)

Invion is developing PhotosoftTM technology as a novel next generation Photodynamic Therapy (PDT). PDT uses non-toxic photosensitisers and light to selectively kill cancer cells and promote an anti-cancer immune response. Less invasive than surgery and with minimal side effects, PDT offers an alternative treatment option aimed at achieving complete tumour regression and long-lasting remission.

personal use only

Meeting Clinical Needs

Demonstrated

Efficacy,

Protective

Immunity

Multiple

Cancers, Future

Potential

Sources of Value Creation

• Major disease areas: Cancer, atherosclerosis, infectious diseases
• Advancing Photosoft™ technology - novel PDT photosensitiser INV043
• Collaboration with world class expertise (Hudson Institute, Peter Mac)
• Regression of established tumours across multiple cancer types
• Immune response, protective immunity
• Strong therapeutic profile: Non-toxic at 100x therapeutic dose
• Clinical stage cancer program
• Multiple cancer indications in Asia Pacific Territories2
• Expanded Disease Areas: Atherosclerosis and Infectious Diseases (AID)
• Clinical trials across multiple cancer indications in 2022 and beyond
• Core clinical development funded by The Cho Group, inventor and owner of the Photosoft™ technology
• Expansion of Territories in AID1 and cancer2

2

r

• Includes Asia and Oceania (other than Australia and New Zealand, which are covered under a pre-existing distribution and licence agreement with RMW), and excludes Middle East, Russia and the specified territories of China, Hong Kong, Macau and Taiwan.

• Includes all Asia Pacific countries excluding China (other than Hong Kong, which is included in the Territory), Macau, Taiwan, Japan and South Korea. Invion's rights with respect to development
  and distribution of Photosoft™ technology in Australia and New Zealand will continue to be covered under the pre-existing agreements with RMW. Closing of transaction subject to shareholder approval.

Photodynamic therapy (PDT)

Autophagy

onlyuse personal4 r

PDT is a proven cancer

therapy. Photosoft™ technology has made dramatic improvements and expands its applications

Tumour regression across

multiple cancer types,

formulations enable multiple

routes of administration

Selectively accumulates

in cancer cells and

rapidly clears from non-

cancerous tissue

Attractive therapeutic profile, highly potent and non-toxic

Absorbs light in wavelengths to "light up" a tumour (diagnostic) or generates reactive oxygen species (ROS) that kills cancer cells (therapeutic)

Triggers immune response

and provides

protective immunity